Greenlight Capital DNABW trades
David Einhorn
David Einhorn GINKGO BIOWORKS -CW27 stake
total: 357
Trades details
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2021 Q3
- Held for:
- 2 quarters
- Latest activity:
- 2022 Q1
According to 2026 Q2 report, David Einhorn doesn't hold any GINKGO BIOWORKS -CW27 (DNABW) shares. To date, the estimated cost basis is nearly $3.39 for "buy" trades and estimated average "sell" price is $2.24. Greenlight Capital first purchased DNABW in 2021 Q3, initially acquiring 91,000 shares. Since the initial investment in GINKGO BIOWORKS -CW27 (DNABW), Greenlight Capital has made 1 more transaction.
When did David Einhorn sell GINKGO BIOWORKS -CW27 (DNABW)?
David Einhorn sold off the entire GINKGO BIOWORKS -CW27 (DNABW) position in 2022 Q1.
When did David Einhorn buy GINKGO BIOWORKS -CW27 (DNABW)?
David Einhorn first invested in GINKGO BIOWORKS -CW27 (DNABW) in 2021 Q3 at the reported quarter-end price of $3.38 per share.
What's the cost basis of Greenlight Capital's DNABW stake?
The estimated cost basis for GINKGO BIOWORKS -CW27 (DNABW) stake is around $3.39 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $3.38
- Weighted AVG sell price:
- $2.24
David Einhorn's historical trades in GINKGO BIOWORKS -CW27
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q1
|
0.00%
|
0
|
$2.24
|
|
-100% (-91,000)
|
-0.01%
|
|
2021 Q3
|
0.02%
|
91,000
|
$3.38
|
$308,000
|
new
|
+0.02%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.